Navigation Links
A leukemia drug kills cancerous T-cells while sparing normal immunity
Date:1/25/2012

BOSTON, MALeukemic cutaneous T-cell lymphoma (L-CTCL) is a leukemia arising from T-cells, a type of white blood cell. This cancer can involve the skin and other organs, and patients often die within three years.

Rachael A. Clark, MD, PhD, BWH assistant professor of dermatology and associate dermatologist and Thomas Kupper, MD, BWH Department of Dermatology chairman and their colleagues now report a new study that low-dose Campath (alemtuzumab) not only treats patients with L-CTCL but does so without increasing their risk of infections.

The study was electronically published on January 18, 2012 in Science Translational Medicine.

Campath was previously believed to kill all lymphocytes (T-cells and B-cells) in the body and render patients susceptible to infections. However, Clark and Kupper found that Campath only kills T-cells that enter the bloodstream, but it spares a newly discovered population of T-cells that live long-term in the tissues.

"We noticed that our patients were not getting infections, and we looked in the skin. We saw healthy T-cells remaining there despite the fact that there were no T-cells in the blood," said Clark. "We used to believe that most T-cells responsible for protecting against infection were in the bloodstream. But we now realize that highly protective T-cells also inhabit tissues such as the skin, lungs and gastrointestinal tract. It is these tissue resident T-cells that are critical in protecting us from infection on a day-to-day basis."

By showing that Campath kills circulating T-cells, including the cancerous T-cells, but spares tissue resident T-cells, Clark and Kupper have shown that Campath effectively treats L-CTCL while sparing normal immunity. Their findings are also the first demonstration in human beings that tissue resident T-cells provide frontline immune protection of the skin.

"We're very grateful to our patients for entrusting us with their care and for teaching us important lessons about the immune system." said Clark.

In a companion piece, Mark Davis, PhD, Stanford University School of Medicine, called the work a "translational tour de force."


'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert

Related medicine news :

1. Penn researchers find genetic link to leukemias with an unknown origin
2. High Rates of Childhood Leukemia Seen in Iraq Province
3. International study confirms doubling of childhood leukemia rates in southern Iraq
4. Cells of aggressive leukemia hijack normal protein to grow
5. Targeting leukemia cells gene addiction presents new strategy for treatment
6. 2010 recipient of Minority Scholar Award will conduct clinical research on leukemia
7. 2010 Recipient of Minority Scholar Award Will Conduct Clinical Research on Leukemia
8. New gateway to treat leukemia and other cancers
9. Targeting cell pathway may prevent relapse of leukemia
10. Autograph Store Sponsors The Leukemia Ball Charity Auction
11. Leukemia-related protein 16 and colorectal carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Bo Chen, PhD is the ... will receive his award during the Plenary Session at ASLMS 2017, the Annual Conference ... in San Diego, California April 5-9, 2017. , During the Plenary Session on ...
(Date:2/27/2017)... ... February 27, 2017 , ... It’s no secret that ... leads to a host of health issues, including urinary incontinence. However, results published ... discovered that good overall muscle strength in older women, particularly in the abdominal ...
(Date:2/27/2017)... ... February 27, 2017 , ... Hotze Health & Wellness ... Brandl as its New Guest Director. , Brandl is a dynamic and ... career. He began his professional career at Omnium Worldwide, now known as West ...
(Date:2/27/2017)... ... 2017 , ... Robert E. Burke, MD, PhD, had a successful career as ... life experiences could have led him down a much different path. , In his ... Perseverance and Pediatrics,” Dr. Burke shares a personal account of the tribulations he encountered ...
(Date:2/27/2017)... ... February 27, 2017 , ... Anahata Ananda of ... is happy to announce her “Spring Rejuvenation in Sedona” personally tailored retreats. For ... offer the winter-weary soul an excellent opportunity to come out of hibernation and ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017 The report "(CTMS)  Clinical Trial Management ... Based, Site Based), By Delivery Mode (Web, Cloud, On Premise), By End ... Report, Regional Outlook (U.S., Canada , Germany ... , Russia , China , ... Korea , Taiwan , Brazil ...
(Date:2/27/2017)... -- Halyard Health, Inc. (NYSE: HYH ) today ... 2017 outlook and related key planning assumptions. Executive Summary ... 2 percent increase compared to the prior year. ... million compared to net income of $15 million in the ... $24 million compared to adjusted net income of $27 million ...
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
Breaking Medicine Technology: